| description |
New antituberculosis drug FS-1 inducing drug resistance reversion was used in this work in combination with anti-mycobacterial antibiotics in an experiment on 105 laboratory guinea pigs infected with the multidrug resistant (MDR) strain M. tuberculosis (Mtb) SCAID 187.0 (CP012506). One group of animals was not infected and used as a negative control. Genetic changes in the Mtb population were analysed during the trial by sequencing of Mtb isolates from four groups of animals: group 2 (positive control, not treated), group 3 (treated solely with antibiotics), group 4 (antibiotics + 2.5 mg/kg FS-1) and group 5 (antibiotics + 4.0 mg/kg FS-1). The following antibiotics were used in this study: pyrazinamide (per os 100 mg/kg), cycloserine (per os 20.0 mg/kg), prothionamide (per os 20.0 mg/kg), capreomycin (intramuscular 20.0 mg/kg) and amikacin (intramuscular 50.0 mg/kg). The therapy with the antibiotics lasted for 60 days. |